1Hoffmann S, Burchert A, Wunderlich A, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid Cancer cell lines[J]. Endocrine, 2007, 31(2): 105-113.
2Prichard CN, Kim S, Yazici YD, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma[J]. Laryngoscope, 2007, 117(4): 674-679.
3Lothaire P, de Azambuja E, Dequanter D, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation[J]. Head Neck, 2006, 28(3): 256-269.
4O-charoenrat P, Rhys-Evans P, Modjtahedi H, et al. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells[J]. Clin Exp Metastasis, 2000, 18(2): 155-161.
5Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck(HNC)[J]. J Clin Oncol, 2005, 23(16S): 5504.
6Karamouzis M, Friedland D, Johnson R, et al. Phase II trial of pemetrexed(P)and bevacizumab(B)in patients(pts)with recurrent or metastatic head and neck squamous cell carcinoma(HNSCC):an interim analysis[J]. J Clin Oncol, 2007, 25(18S): 6049.
7Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies[J]. Cancer Res, 2005, 65(3): 671-680.
8Khan AJ, King BL, Smith BD, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma[J]. Clin Cancer Res, 2002, 8(2): 540-548.
9Gillison ML, Glisson BS, O’leary E, et al. Phase II trial of trastuzumab(T), paclitaxel(P)and cisplatin I in metastatic(M)or recurrent I head and neck squamous cell carcinoma(HNSCC): response by tumor EGFR and HER2/neu status[J]. J Clin Oncol, 2006, 24S(18Part 1): 282.
10Widakowich C, de Castro G Jr, de Azambuja E, et al. Review: side effects of approved molecular targeted therapies in solid cancers[J]. Oncologist, 2007, 12(12): 1443-1455.
